IOVA logo

Iovance Biotherapeutics (IOVA) Company Overview

Profile

Full Name:

Iovance Biotherapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 15, 2010

Indexes:

Not included

Website:

http://www.iovance.com

Description:

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing products for cancer immunotherapy using the patient's own immune system to destroy cancer cells. The company utilizes its own manufacturing process for tumor therapy, which has reduced manufacturing time from 5-6 weeks to 22 days. In addition, Iovance Biotherapeutics is conducting a number of trials for the treatment of metastatic melanoma, cervical cancer, head and neck cancer, lung cancer, and other forms of cancer. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

Key Details

Price

$3.81

Market Cap

$1.25 B(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$164.07 M(+13698.99% YoY)

Annual EPS

-$1.28(+32.28% YoY)

PE Ratio

-

Annual ROE

-57.48%

Annual Debt To Equity

0.00

Beta

1.69

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Feb 27, 2025

Recent annual earnings:

Feb 27, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sep 26, 2013

Analyst ratings

Recent major analysts updates

Mar 3, 25 Truist Securities
Buy
Mar 3, 25 Goldman Sachs
Buy
Mar 3, 25 Chardan Capital
Buy
Feb 28, 25 Piper Sandler
Neutral
Feb 28, 25 HC Wainwright & Co.
Buy
Feb 28, 25 Baird
Outperform
Jan 31, 25 Piper Sandler
Neutral
Nov 6, 24 HC Wainwright & Co.
Buy
Oct 24, 24 UBS
Buy
Aug 12, 24 HC Wainwright & Co.
Buy

Screeners with IOVA included

Growing Shares Outstanding
US stocks
Stocks with high beta
Stocks below SMA 200
Most recommended stocks
Stocks below analysts price target
Healthcare sector
All stocks
NASDAQ Listed Companies
Biotechnology industry

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$3.81
IOVA price is $3.81

Price All-time High

$159.00
IOVA price is currently -97.60% below its historical high of $159.00

Price Analysts Target

$18.00
IOVA price is currently -78.83% lower than the consensus analysts' forecast

Price Today Change

-2.79%
IOVA price is down -2.79% today

Price YTD Change

-48.51%
IOVA price is down -48.51% since January 1st

Price 3-Year Change

-71.09%
IOVA price is down -71.09% over the past 3 years

Market cap

Market Cap

$1.25 B
IOVA market capitalization is $1.25 billion

Market Cap 3-Year Change

-39.69%
IOVA market capitalization is down -39.69% over the past 3 years

Market Cap All-time High

$7.72 B
IOVA market capitalization is currently -83.83% below its historical high of $7.72 billion

Market Cap Sector Rank

77.68%
IOVA market capitalization is higher than 77.68% of companies in Healthcare sector

Technical

Beta

1.69
IOVA beta is 1.69

200-day SMA

$8.38
IOVA price is currently -54.52% below its 200-day simple moving average

14-day RSI

20.74
IOVA 14-day relative strength index is 20.74

30-day Relative Volume

0.74
IOVA 30-day relative volume is 0.74

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$164.07 M
IOVA annual revenue is $164.07 million

Annual Revenue Analysts Estimate

$448.99 M
IOVA annual revenue is currently -63.46% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+13698.99%
IOVA annual revenue is up +13698.99% year-on-year

Annual Revenue Sector Rank

61.11%
IOVA annual revenue is higher than 61.11% of companies in Healthcare sector

Profit

Annual Gross Profit

$40.08 M
IOVA annual gross profit is $40.08 million

Annual Gross Margin

24.43%
IOVA annual gross profit margin is 24.43%

Annual Operating Profit

-$395.28 M
IOVA annual operating income is -$395.28 million

Annual Operating Margin

-240.92%
IOVA annual operating profit margin is -240.92%

Annual Net Income

-$372.18 M
IOVA annual net profit is -$372.18 million

Annual Net Margin

-226.84%
IOVA annual net profit margin is -226.84%

EPS

Annual EPS

-$1.28
IOVA annual earnings per share is -$1.28

Annual EPS Analysts Estimate

-$0.80
IOVA annual earnings per share is currently +60.24% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+32.28%
IOVA annual earnings per share is up +32.28% year-on-year

Annual EPS Sector Rank

53.45%
IOVA annual earnings per share is higher than 53.45% of companies in Healthcare sector

ROA & ROE

Annual ROA

-44.02%
IOVA annual return on assets is -44.02%

Annual ROE

-57.48%
IOVA annual return on equity is -57.48%

EBIT & EBITDA

Annual EBIT

-$395.28 M
IOVA annual earnings before interest & taxes is -$395.28 million

Annual EBITDA

-$351.67 M
IOVA annual EBITDA is -$351.67 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
IOVA price to earnings ratio value is unknown

PE Ratio Sector Rank

-
IOVA price to earnings ratio is unknown

PB Ratio

PB Ratio

1.76
IOVA price to book ratio is 1.76

PB Ratio Sector Rank

56.72%
IOVA price to book ratio is higher than 56.72% of companies in Healthcare sector

PS Ratio

PS Ratio

7.61
IOVA price to sales ratio is 7.61

PS Ratio Sector Rank

73.86%
IOVA price to sales ratio is higher than 73.86% of companies in Healthcare sector

Enterprise value

Enterprise Value

$1.19 B
IOVA enterprise value is $1.19 billion

Enterprise Value Sector Rank

76.08%
IOVA enterprise value is higher than 76.08% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.39
IOVA EV/EBITDA is -3.39

EV/EBITDA Sector Rank

28.48%
IOVA EV/EBITDA is higher than 28.48% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

3.74
IOVA annual current ratio is 3.74

Annual Quick Ratio

3.31
IOVA annual quick ratio is 3.31

Leverage

Annual Debt To Equity

0.00
IOVA annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
IOVA annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

5
IOVA piotroski f-score is 5

Altman Z-Score

-0.73
IOVA altman z-score is -0.73

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$910.43 M
IOVA annual total assets is $910.43 million

Annual Non Current Assets

$453.41 M
IOVA annual long term assets is $453.41 million

Annual Current Assets

$457.02 M
IOVA annual total current assets is $457.02 million

Annual Cash & Cash Equivalents

$115.69 M
IOVA annual cash & cash equivalents is $115.69 million

Equity

Annual Book Value

$710.40 M
IOVA annual book value is $710.40 million

Annual Working Capital

$334.68 M
IOVA annual working capital is $334.68 million

Liabilities

Annual Total Liabilities

$200.02 M
IOVA annual total liabilities is $200.02 million

Annual Total Long Term Liabilities

$77.68 M
IOVA annual total long term liabilities is $77.68 million

Annual Current Liabilities

$122.34 M
IOVA annual total current liabilities is $122.34 million

Annual Accounts Payable

$27.51 M
IOVA annual accounts payable is $27.51 million

Debt

Annual Total Debt

$58.26 M
IOVA annual total debt is $58.26 million

Annual Total Debt 1-Year Change

-23.2%
IOVA annual total debt is down -23.2% year-on-year

Annual Long Term Debt

$45.37 M
IOVA annual long term debt is $45.37 million

Annual Short Term Debt

$12.90 M
IOVA annual short term debt is $12.90 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$559.35 M
IOVA annual total expenses is $559.35 million

Annual Operating Expenses

$435.35 M
IOVA annual total operating expenses is $435.35 million

Annual Cost Of Goods Sold

$124.00 M
IOVA annual cost of goods sold is $124.00 million

Annual SGA

$153.02 M
IOVA annual SGA is $153.02 million

Annual D&A

$43.61 M
IOVA annual depreciation & amortization is $43.61 million

Annual Interest Expense

-
IOVA annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$352.98 M
IOVA annual cash flow from operations is -$352.98 million

Annual CFO 1-Year Change

+2.44%
IOVA annual cash flow from operations is up +2.44% year-on-year

Annual CFI

-$96.41 M
IOVA annual cash flow from investing activities is -$96.41 million

Annual CFI 1-Year Change

+37.9%
IOVA annual cash flow from investing activities is up +37.9% year-on-year

Annual CFF

$390.66 M
IOVA annual cash flow from financing activities is $390.66 million

Annual CFF 1-Year Change

-15.62%
IOVA annual cash flow from financing activities is down -15.62% year-on-year

Free CashFlow

Annual FCF

-$364.05 M
IOVA annual free cash flow is -$364.05 million

Annual FCF 1-Year Change

+5.22%
IOVA annual free cash flow is up +5.22% year-on-year

CAPEX

Annual CAPEX

$11.07 M
IOVA annual capital expenditures is $11.07 million

Annual CAPEX 1-Year Change

-50.34%
IOVA annual capital expenditures is down -50.34% year-on-year

Institutional Ownership

Similar stocks

TXG logo
10x Genomics (TXG)
VRDN logo
Viridian Therapeutics (VRDN)
NVAX logo
Novavax (NVAX)
ANIP logo
ANI Pharmaceuticals (ANIP)
INMD logo
InMode (INMD)
BLFS logo
BioLife Solutions (BLFS)
PHR logo
Phreesia (PHR)
AMPH logo
Amphastar Pharmaceuticals (AMPH)
ARDX logo
Ardelyx (ARDX)

FAQ

  • What is the ticker symbol for Iovance Biotherapeutics?
  • Does Iovance Biotherapeutics pay dividends?
  • What sector is Iovance Biotherapeutics in?
  • What industry is Iovance Biotherapeutics in?
  • What country is Iovance Biotherapeutics based in?
  • When did Iovance Biotherapeutics go public?
  • Is Iovance Biotherapeutics in the S&P 500?
  • Is Iovance Biotherapeutics in the NASDAQ 100?
  • Is Iovance Biotherapeutics in the Dow Jones?
  • When was Iovance Biotherapeutics's last earnings report?
  • When does Iovance Biotherapeutics report earnings?
  • Should I buy Iovance Biotherapeutics stock now?

What is the ticker symbol for Iovance Biotherapeutics?

The ticker symbol for Iovance Biotherapeutics is NASDAQ:IOVA

Does Iovance Biotherapeutics pay dividends?

No, Iovance Biotherapeutics does not pay dividends

What sector is Iovance Biotherapeutics in?

Iovance Biotherapeutics is in the Healthcare sector

What industry is Iovance Biotherapeutics in?

Iovance Biotherapeutics is in the Biotechnology industry

What country is Iovance Biotherapeutics based in?

Iovance Biotherapeutics is headquartered in United States

When did Iovance Biotherapeutics go public?

Iovance Biotherapeutics's initial public offering (IPO) was on October 15, 2010

Is Iovance Biotherapeutics in the S&P 500?

No, Iovance Biotherapeutics is not included in the S&P 500 index

Is Iovance Biotherapeutics in the NASDAQ 100?

No, Iovance Biotherapeutics is not included in the NASDAQ 100 index

Is Iovance Biotherapeutics in the Dow Jones?

No, Iovance Biotherapeutics is not included in the Dow Jones index

When was Iovance Biotherapeutics's last earnings report?

Iovance Biotherapeutics's most recent earnings report was on Feb 27, 2025

When does Iovance Biotherapeutics report earnings?

The next expected earnings date for Iovance Biotherapeutics is May 9, 2025

Should I buy Iovance Biotherapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions